Labra ZMG, Cortés FJ, Rangel RMP, Solórzano SF, Pacheco RDO

Language: Spanish
References: 9
Page: 121-124
PDF size: 265.59 Kb.

ABSTRACT

Suppurative regional lymphadenitis and injection site abscess are the most frequent forms of BCG vaccine adverse events.
Objective. Analysis of a series of cases with regional bcg vaccine lymphadenitis. Material and Methods. Adescriptive study of a BCG-vaccinated children serie who developed regional lymphadenitis and were referred to a third-level hospital.
Results. Twelve children, seven men and five women, with a median age of 7.1 months (range 3-11 months) were included. In 11 (91%) children the bcg vaccine was applied within the neonatal period. The mean age of presentation of lymphadenitis was at four months (range 1-9 months). Ten cases had localization in the axillary region, one supraclavicular and one at the cervical level. All lesions measured less than 3 cm. No cystic type lesions were detected, five were suppurative and seven non-suppurative. In two of the children with suppurative lesions, excisional biopsy was performed; in the non-suppurative four received antibiotic treatment and in six were also done excisional biopsy. The resolution time of the lesion was similar in those who received isoniazid treatment, as in those who did not receive it. All 12 patients had a satisfactory outcome.
Discussion. The approach and management of bcg lymphadenitis in our hospital was very diverse, probably because there is no international consensus for its management. In the suppurative form the management difference is greater, ranging from conservative treatment, tuberculosis therapy, ganglion aspiration, or a combination of antifimic plus aspiration.

REFERENCES

1. Lotte, A., Wasz-Hockert, O., Poisson, N., Engbaek, H., Landmann, H. y Quast, U., “Second iuatld study on complications induced by intradermal bcg-vaccination”, Bull Int Union Tuberc Lung Dis, 1988, 63: 47-59.

2. Moreira, T.N., Moraes-Pinto, M.I., Costa-Carvalho, B.T., Grumach, A.S. y Weck, L.Y., “Clinical management of localized bcg adverse events in children”, Rev Inst Med Trop Sao Paulo, 2016, 58: 84.

3. Engelis, A., Kakar, M., Meikšāns, R. y Petersons, A., “bcg-ssi(®) vaccine-associated lymphadenitis: incidence and management”, Medicina (Kaunas), 2016, 52 (3): 187-191.

4. Li, R.L., Wang, J.L., Wang, X.F. y Wang, M.S., “Tuberculosis in infants: a retrospective study in China”, Springerplus, 2016, 5: 546.

5. Nissen, T.N., Birk, N.M., Kjærgaard, J., Thøstesen, L.M., Pihl, G.T., Hoffmann, T., Jeppesen, D.L., Kofoed, P.E., Greisen, G., Benn, C.S., Aaby, P., Pryds, O. y Stensballe, L.G., “Adverse reactions to the Bacillus Calmette-Guérin (bcg) vaccine in new-born infants: an evaluation of the Danish strain 1331 ssi in a randomized clinical trial”, Vaccine, 2016, 34 (22): 2477-2482.

6. Goraya, J.S. y Virdi, V.S., “Bacille Calmette-Guérin lymphadenitis”, Postgrad Med J, 2002, 78 (920): 327-329.

7. Venkataraman, A., Yusuff, M., Liebeschuetz, S., Riddell, A. y Prendergast, A.J., “Management and outcome of Bacille Calmette-Guérin vaccine adverse reactions”, Vaccine, 2015, 33 (41): 5470-5474.

8. Cuello-García, C.A., Pérez-Gaxiola, G. y Jiménez Gutiérrez, C., “Treating bcg-induced disease in children”, Cochrane Database Syst Rev, 2013, 31 (1): cd008300.

9. Bukhari, E., Alaklobi, F., Bakheet, H., Alrabiaah, A., Alotibi, F., Aljobair, F., Alshamrani, M., Alaki, E., Alnahdi, F., Alodyani, A. y Alzamil, F., “Disseminated bacille Calmette-Guérin disease in Saudi children: clinical profile, microbiology, immunology evaluation and outcome”, Eur Rev Med Pharmacol Sci, 2016, 20 (17): 3696-3702.